搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
5 Thyroid Myths Doctors Say to Stop Believing Now
Experts share thyroid myths to stop believing now. Mythbuster: While these symptoms can point to a thyroid issue, “weight ...
emjreviews.com
6 天
Thyroid Diseases Increase Cancer and Osteoporosis Risks in Sjögren’s Syndrome
Thyroid diseases in primary Sjögren’s syndrome patients increase risks of malignancy and osteoporosis, driven by immune ...
6 天
on MSN
Understanding your thyroid, the master of metabolism
In this latest Texas Tech HSC expert column, Dr. Mohamad Sidani looks at the importance of thyroid health on the metabolism.
Medscape
7 天
Should Patients With Thyroid Issues Take GLP-1s? It Depends
Obesity and family practice experts share when it’s safe to prescribe GLP-1 receptor agonists to patients with thyroid ...
10 天
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the ...
Optics
8 天
ICFO near-IR platform sees details of thyroid pathologies
ICFO has now used the LUCA platform to characterize the thyroid tissue with simultaneous anatomical measurements, the first ...
Knowridge
4 天
How to prevent thyroid diseases in the natural way
The thyroid is a small, butterfly-shaped gland in your neck that plays a big role in your overall health. It produces ...
Pharmaceutical Technology
1 天
Vemurafenib by F. Hoffmann-La Roche for Thyroid Cancer: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thyroid Cancer.
Monthly Prescribing Reference
10 天
Veligrotug Beneficial for Patients With Chronic Thyroid Eye Disease
Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.
ophthalmologytimes
8 天
Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for ...
THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈